AML

FDA Grants Fast Track Designation to BST-236 for Older Adults With Acute Myeloid Leukemia

August 04, 2020

The FDA has granted a Fast Track designation to BST-236 for the treatment of patients with acute myeloid leukemia who are 75 years or older or have comorbidities that preclude the use of intensive induction chemotherapy.

Treatment Landscape for Acute Myeloid Leukemia Appears Hopeful for Patients

July 31, 2020

Eunice Wang, MD, discusses the excitement she has experienced in the treatment landscape of acute myeloid leukemia over the last several years due to the number of new treatment options approved by the FDA.

Sorafenib Maintenance May Prevent Recurrence After Transplant in FLT3-ITD+ AML

July 21, 2020

The risk of relapse or death was reduced by 61% with sorafenib maintenance compared with placebo following allogeneic hematopoietic stem cell transplantation in patients with FLT3-ITD–positive acute myeloid leukemia.

Expansion of AML Treatment Landscape Underscores Importance of Molecular Testing

July 17, 2020

In an interview with Targeted Oncology, Yousef Zakharia, MD, discussed the current treatment landscape for acute myeloid leukemia and how he goes about sequencing the available agents when he treats patients in clinic.

Exploring the Data for AML Treated With Magrolimab and Azacitidine

July 17, 2020

Naval G. Daver, MD, discusses a phase 1b trial evaluating the efficacy of margolimab and azacitidine combination for patients with acute myeloid leukemia.

Azacitidine Plus APR-246 Induces Promising Activity, Safety in TP53-Mutant MDS and AML

July 14, 2020

In an interview with Targeted Oncology, Thomas Cluzeau, MD, PhD, discussed the findings from the phase 2 study of azacitidine plus APR-246 as treatment of patients with TP53-mutant myelodysplastics syndrome and acute myeloid leukemia. He also highlighted the next steps for this treatment regimen.

Phase 3 Trial of Pracinostat Plus Azacitidine Combination in AML Discontinued

July 06, 2020

A phase 3 study evaluating pracinostat in combination with azacitidine for patients with acute myeloid leukemia ineligible for standard intensive chemotherapy has been discontinued.

Phase 3 Study Confirms Benefit of Venetoclax/LDAC in Chemotherapy-Ineligible AML

July 03, 2020

A new randomized placebo-controlled study finds patients with acute myeloid leukemia who cannot undergo intensive chemotherapy have improved outcomes when given venetoclax in addition to low-dose cytarabine.

Managing Patients With Myeloid Malignancies During and After the Global COVID-19 Pandemic

June 24, 2020

During the Virtual 25th Congress of the European Hematology Association (EHA), a group of physicians described their experiences and recommendations for managing patients with myeloid malignancies during the COVID-19 pandemic and after.

Azacitadine Plus Pevonedistat Shows Efficacy in MDS/CMML or LB AML

June 23, 2020

Mikkael Sekeres, MD, discusses a phase 2 study of pevonedistat plus azacitidine versus azacitadine monotherapy in patients with higher-risk myelodysplastic syndromes /chronic myelomonocytic leukemia or low-blast acute myelogenous leukemia.